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Abstract 
The role of inflammatory mediators in surgical repair has 
not been delineated. Tumor necrosis factor alpha (TNFa) 
and interleukin-1 beta (IL-1~) are cytokines, which are 
recognized as potent stimulators of the initial 
inflammatory response. In our study we tested the 
hypothesis that stimulation by the inflammatory cytokines 
tumor necrosis factor (TNF) and interleukin-1 (IL-1) are 
necessary for osseous and soft tissue wound healing. A 
calvarial osteotomy, 1mm in diameter, was created in three 
groups of mice: one with targeted deletions of the TNF 
receptors p55 and p75, one with targeted deletions of the 
IL-1 receptor type I, and one with wild-type (control) 
mice. Bone healing was assessed by quantitative 
histomorphometry. Because three mice died, the number of 
animals in the experiment was not large enough to produce 
viable statistical results. However, we observed reduced 
osseous healing between the experimental groups (TNF p55-
/p75- and IL-1 -/-) and the control group at Day 14. 
For the soft tissue experiment, a 1.5mm punch biopsy was 
created in the scalp using the same genetically altered 
mice that were used for the hard tissue experiment. At two 
3 
and four days after wounding, the experimental and control 
mice showed similar healing rates. However, at seven days 
after wounding, there was complete healing for the wild-
type mice and significantly less connective tissue and 
epithelial healing for the TNF p55-/p75- and IL-lR -/-
animals, as determined by an F-test (p<0.05). Although TNF 
and IL-1 activity is generally thought to inhibit wound 
healing, these results demonstrate that TNF and IL-1 are 
necessary for maintaining the normal progression of both 
soft and hard tissue repair following a surgical wound. 
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Introduction 
According to the 1990 American Dental Association survey of 
dental procedures, more than 720,000 apical surgeries are 
performed each year. As a consequence, our interest lies 
in the progression of wound healing in both the osseous and 
soft tissue models. Tumor necrosis factor and interleukin-
1 are pro-inflammatory cytokines and their role in the 
early stages of repair is widely accepted [l, 2]. Most 
studies have investigated wound healing in the presence of 
infection or sepsis [3-5]; however, little is known about 
the effects of TNF and IL-1 on normal wound healing. By 
creating a wound in an environment that normally heals 
well, we tested the role of these two cytokines on animals 
that lack the ability to respond to TNF and IL-1 and 
compared the results to control animals. Therefore, the 
purpose of these experiments was to test the hypothesis 
that TNF and IL-1 activities are necessary in the normal 
wound healing process. 
The purpose of this literature review is to evaluate the 
scalp and calveria as models, and assess the biological 
activities of the cytokines TNF and IL-1 and their roles in 
wound healing. 
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Review of Literature 
Endochondral Bone 
The base of the skull and most of the skeletal system 
develop through the process of endochondral ossification. 
This type of ossification begins with a hyaline cartilage 
matrix and its perichondrium. After vasculature invasion 
of the cartilage, the chondrocytes hypertrophy and die and 
then the cartilage matrix is removed. The perichondrium 
then becomes the periosteum when the osteoprogenitor cells 
become osteoblasts and begin the production of bone. 
Internally, the osteoblasts produce bone matrix at primary 
ossification centers and later at secondary ossification 
centers. Externally the periosteal osteoblasts produce 
what eventually becomes the dense cortical plate. The 
newly formed bone is then remodeled into the mature form of 
bone. 
Intramembraneous Bone 
Other than the bones in the base of the skull, the 
remaining skull bones are formed by intramembraneous 
ossification. At the site where the bone is to be 
developed, immature mesenchymal cells aggregate to form an 
immature connective tissue. These cells differentiate to 
form immature osteoblasts and then they mature into 
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osteoblasts and begin to produce trabeculae of woven bone. 
As the trabeculae are being formed, the cells surrounding 
the bone specialize and form the periosteum. Osteoblasts 
lay down bone matrix beneath the periosteum to form an 
outer layer of compact bone. Remodeling then occurs to 
convert the woven bone to mature bone. The resulting bone 
is indistinguishable from endochondral bone. 
Rational for use of the Calvaria for osseous model 
The calvaria was chosen as a model for the osseous study 
for two reasons. First, it is composed of membranous bone, 
which is the same type of bone found in the maxilla and 
mandible. Second, it is an easily accessible area that 
reduces the trauma of surgery to small animals such as 
mice. Furthermore, several experiments have used calvariae 
as models to study inflammatory responses [6-10]. 
Anatomy of the scalp 
The scalp is usually described as having five layers: the 
skin, the subcutaneous connective tissue, the aponeurosis, 
the loose areolar layer, and the pericranium [11, 12]. 
The skin is the most superficial layer of the scalp and 
contains two distinct layers: the epidermis and the dermis. 
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The skin of the scalp is the thickest of the body, making 
it a good donor site for split thickness grafting. This 
laye J contains hair, sebaceous glands, sweat glands, and 
structures that may also involve the subcutaneous layer. 
The subcutaneous layer of the scalp is a fatty layer like 
elsewhere in the body. However, it differs from the rest 
of the body in that it contains a dense, tough, and 
substantial network of fibrous septa that extends across 
the subcutaneous layer onto the deeper aponeurotic layer. 
This network creates skin stability similar to that on the 
palms of the hands and soles of the feet. 
The third layer of the scalp, the aponeurosis, is 
multilayered in that it contains the musculoaponeurotic 
layer of the frontalis and occipitalis muscles that 
sandwich the galea, a dense layer of collagen that gives 
the scalp most of its tensile strength. 
The fourth layer of the scalp is the loose areolar layer 
that lies beneath the epicranius muscle. It is composed of 
a fine connective tissue that gives the scalp its 
flexibility by allowing the three layers superior to it to 
move as a unit. 
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The deepest layer of the scalp is the pericranium, which is 
the periosteum of the skull. 
Rational for use of the scalp for the soft tissue model 
There are several reasons the scalp was chosen for the 
model. First, as with the calvaria, the scalp is easily 
accessible and limits trauma in small animals. It also has 
the stability to withstand the physical forces placed upon 
it in the caged environment of experimental animals, and it 
has a naturally low bacterial load. Furthermore, 
experiments have shown that healing by secondary intention 
of the scalp with exposed bone is a safe and effective 
method of wound management[13]. 
TNFa ligand 
Tumor necrosis factor plays a key role in the inflammatory 
response and as a mediator of immune reactions [14-16]. 
Its cytotoxic and pro-inflammatory effects are either 
beneficial or injurious depending on the level and duration 
of expression [17]. 
TNFa exists as a free-secreted and a cell-associated form. 
The cell-associated variety is a 26kDa transmembrane pro-
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TNF form and the free variant is secreted as a 17kDa mature 
form. The precursor to mature TNF is the pro-TNF form, 
which is a type II transmembrane protein with the C 
terminus in the extracellular domain and the N-terminus 
inside the cytoplasm. The transmembrane or pro-TNF 
molecule is cleaved proteolytically by the TNF-converting 
enzyme (TCE) between the alanine and valine in the 
extracellular domain to produce the mature, bioactive form 
of TNF [18, 19]. Furthermore, the remaining 26kDa 
transmembrane form of TNF is also active and has been shown 
to mediate the cytotoxic effect of TNF through cell-to-cell 
contact[20-22]. 
Studies have shown the structure of TNF to be a P-sheet 
protein that self-associates non-covalently into a 
symmetrically compact, bell-shaped trimer. Each subunit 
consists almost entirely of antiparallel p-pleated sheets. 
The N terminus is free from the base of the trimer while 
the C-terminus is embedded into the base [23]. Other 
studies have suggested that the trimeric structure of TNF 
is important for its biological function due to the finding 
that when the trimeric bonding of TNF is altered, the TNF 
molecule losses its biological activity [1, 24, 25]. 
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Many immune cells such as monocytes, natural killer cells, 
Band T cells, and granulocytes produce TNF. Also, many 
non-immune cells such as epithelial cells, mast cells, 
Kupffer cells, fibroblasts, osteoblasts, smooth muscle 
cells, keratinocytes, neurons and various tumor cell types 
have been shown to synthesize TNF [l]. TNF synthesis is 
induced by biochemical and physical stimuli. Viruses, 
bacteria and their by-products (LPS), tumor cells, 
interleukin 1 and 2, complement, interferon y (IFN y), 
granulocyte-macrophage colony stimulating factor (GM-CSF), 
and TNF itself, are biochemical examples, while radiation, 
trauma and ischemia are physical examples. 
The location of the TNFa gene is in the major 
histocompatability complex (MHC) and is found on several 
alleles [26]. A notable feature of the MHC is the 
polymorphic characteristics associated with the genes in 
this region; these polymorphisms are linked to the 
variability in TNF production by individuals [26, 27]. 
Since TNF is a potent, central mediator in the 
immunological response, its synthesis is tightly controlled 
by redundant factors to ensure it is not produced to any 
great extent under normal circumstances. TNF is produced 
in minute quantities by quiescent cells. However, it is 
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one of the major secretory products of activated cells. 
Induction of the TNF gene occurs early by any of the 
stimuli mentioned above. Within 15-30 minutes TNF mRNA 
increases dramatically, which implies that the induction 
factors for TNF up-regulation pre-exist in unstimulated 
cells [18]. 
TNF's role in the inflammatory response is primarily 
paracrine in nature. It increases neutrophil margination, 
and activation of the anti-microbial activity of monocytes, 
macrophages, neutrophils, and eosinophils [28]. At the 
wound site, TNF activity stimulates angiogenesis, vascular 
permeability, and collagen synthesis and osteoclast 
activity. At the appropriate level and duration of TNF 
activity, these are beneficial responses to a trauma and 
aid in the remodeling of the wound tissue. Excessive or 
chronic production induces fever, anorexia, and muscle 
degradation (to increase the amino-acid pool for protein 
synthesis). In large concentrations, septic shock results 
with possible fatal results [16, 29, 30]. 
TNFa receptors 
The varied biological activities of TNF are mediated 
through two distinct but structurally homologous receptors. 
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TNF receptor type I (p55 or p60) has a molecular weight of 
60kDa where TNF receptor type II is 80kDa (p75 or p80). 
Experiments using receptor specific anti-bodies, receptor 
specific ligands, and mice genetically deficient for either 
p55 or p75 indicate that p55 is the primary signaling 
receptor through which the majority of inflammatory 
responses attributed to TNF occur [31-35]. Both receptors 
are transmembrane glycoproteins and members of the TNF 
receptor superfamily, which is characterized by multiple 
cystine rich, repeats of about 40 amino acids in the 
extracellular domain [36]. The intercellular domain of the 
two receptors is not homologous, suggesting that the 
receptors utilize different pathways for intracellular 
signal transduction [16]. With the exception of red blood 
cells, TNFR2 is found on all cells, but in greater numbers 
on cells of hematopoietic origin. TNFRl is more prevalent 
on all other cells. Both receptors bind to TNF with high 
affinity [37, 38]. Both receptors exist in soluble forms 
and are also termed TNF-binding proteins because they bind 
to the TNF molecule and compete with the cell associated 
TNF receptors for TNF. The soluble forms of the receptors 
are produced by proteolytic cleavage of the extracellular 
domains, but the specific mechanism is unknown. The role 
of the soluble receptor appears to be a negative feedback 
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mechanism to limit the potentially harmful effects of TNF. 
At high concentrations, the soluble receptors bind to TNF, 
thereby inhibiting the active form of TNF from binding to a 
receptor and stimulating a cellular response. At low 
concentrations, the soluble TNF receptors may augment the 
long-term effects of TNF by providing a reservoir of 
bioactive TNF that is slowly released [16]. 
TNF Signal Transduction 
Cellular responses to TNF are initiated by the interaction 
TNF and its receptors. Once the receptor has been 
activated, they in turn activate receptor-associated 
factors or recruit other downstream factors to the receptor 
complex. 
signals. 
Intracellular signaling molecules then transduce 
TNFRl Signaling 
The majority of TNF activities are mediated by TNFRl 
exclusively [39, 40]. The various activities are most 
likely to be mediated by the intracellular functional 
domains of the TNFRl and the proteins with which the TNFRl 
functional domains interact. There are three functional 
domains in the intracellular region of TNFRl thought to be 
responsible for transferring signals from the TNF bound 
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extracellular domain to the intracellular adapters. The 
three domains, the C-terminal death domain and the adjacent 
N-Smase (neutral sphingomyelinase) and A-Smase (acidic 
sphingomyelinase) appear to be activated by protein-to-
protein interaction. TRADD (TNFRl associated death domain 
protein), binds to the death domain on TNFRl; FAN (Factor 
associated with N-Smase activation), binds to the NSD 
domain and phosphatidyl-choline-specific phospholipase c 
(PC-PLC), binds to ASD [41]. TNFRl death domain regulates 
both the apoptotic and antiapoptotic pathways [42]. 
TNFR2 Signaling 
TNFR2 direct signaling is less extensive than TNFRl and 
seems to be limited to the cells of the immune system. It 
appears that the main function of TNFR2 is to potentiate 
the effects of TNFRl. TNFR2 also seems to regulate TNF 
effects such as Band T cell proliferation, induction of 
NF-kB, and cytotoxicity [43, 44]. Recent studies indicate 
that TNF stimulation of TNFR2 down regulates human and 
murine T-cells by inducing apoptosis [45, 46]. However, 
the signaling mechanism for TNFR2 induced apoptosis is not 
understood at this time. 
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TNF ~ / Lymphotoxin a 
TNF ~, which has been renamed Lymphotoxin a, is another 
member of the TNF ligand family that has inflammatory 
properties similar to TNF. It binds to the TNFRl and TNFR2 
receptors as well as the lymphotoxin beta-receptor and 
herpes virus entry mediator (HVEM)to control a wide range 
of innate and adaptive immune responses. Recent studies 
have discovered various downstream signaling molecules: 
caspases, phospholipases, three mitogen activated protein 
kinase pathways, and the NF-KB activation cascade. The 
signaling molecules that initiate these events, as well as 
the death domain, are primarily unique to the TNF/nerve 
growth factor family [39, 44, 47]. 
Interleukin-1 ligand 
IL-1 is a potent, highly inflammatory cytokine that has a 
very fine margin between local benefit and systemic 
toxicity. Systemically, IL-1 is a potent inducer of 
hypotension and shock, so together with TNF it can be 
lethal. The gene for the characterized members of the IL-1 
family, except IL-18, is found on the long arm of 
chromosome 2[48]. The IL-1 gene group is made up of IL-la, 
IL-1~, and IL-lreceptor antagonist (IL-lRa). Each member is 
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synthesized as a precursor protein: proIL-la and proIL-lP, 
with molecular weights of 3lkDa. Both the proIL-la and the 
mature 17kDa IL-la are biologically active where the proIL-
1p requires cleavage by interleukin -lP converting enzyme 
(ICE) to become a bioactive 17kDa protein [49]. The IL-lRa 
precursor has a leader sequence and is cleaved to its 
mature form and secreted like most proteins. IL-la and P 
are potent agonists; IL-lRa appears to be a pure receptor 
antagonist with no agonist activity in vivo or in vitro 
[ 5 0] . 
Most cells produce IL-1, but the primary producers are 
macrophages and other immunocompetent cells. Locally, it 
results in the release of lipid-derived mediators such as 
platelet activating factor (PAF) and eicosanoids. IL-1 is 
also chemotactic for neutrophils, monocytes, and 
lymphocytes. These actions are the result of IL-l's 
ability to induce other chemotactic chemokines, such as IL-
8, and the upregulation of cell adhesion molecules. 
Compared to TNF, IL-1 is the most potent inducer of 
endothelial cell adhesion molecules. Current research 
suggests a close interaction between immune mediators (IL-
lP), intermediate messengers (NO, prostaglandins), and 
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neurogenic factors (CGRP) in the control of vascular 
function and exacerbation of the inflammatory response 
under pathological conditions [51] .Experiments have shown 
that IL-1 is an essential regulator of the host's response 
to infection and injury, but is not required for 
development or homeostasis in healthy animals [52]. 
Interleukin -la 
The IL-la precursor, (ProIL-la), is synthesized as a 31-kDa 
protein, which is translated in the endoplasmic reticulum, 
is fully active, and remains intracellular [53]. IL-la can 
be cleaved by membrane associated proteases and excreted or 
can be cleaved by extracellular proteases when cells die 
and the ProIL-la is released [54]. It is believed that IL-
la is an autocrine growth factor for three reasons: Pro-IL-
la is synthesized and remains intracellular; the 
intracellular pro-IL-la complexes with IL-lRl and produces 
a ligand receptor complex; and when either pro-IL-la or 
mature IL-la binds to surface IL-lRl, the complex is 
internalized and translocates to the nucleus similar to 
steroid receptors [49]. There is also evidence that the 
precursor of IL-la is transported to the surface of the 
cell where it becomes a bioactive surface bound form [55]. 
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Interleukin-lP 
The pro-IL-lP form is synthesized and remains in the cytosol 
until it is cleaved by interleukin-lP converting enzyme 
(ICE) and transported out of the cell as a mature 17kDa P-
sheet protein; there is no membrane bound form. Its 
elemental function is to induce a wide variety of genes 
during disease. IL-lP is also a potent inducer of enzymes 
for mediators such as prostaglandins, leukotrienes, and 
nitric oxide during the inflammatory response. 
IL-1 Receptors 
There are two primary receptors and one receptor accessory 
protein (IL-lR-AcP) for IL-1. The extracellular domains of 
the receptors and the IL-lR-AcP are members of the 
immunoglobulin superfamily and have a significant homology 
to each other [56, 57]. The two receptors are distinct 
gene products; IL-lRl is an 80kDa glycoprotein found 
primarily on endothelial cells, smooth muscle cells, 
epithelial cells, hepatocytes, fibroblasts, keratinocytes, 
epidermal dendritic cells, and T lymphocytes. IL-lRl has a 
single transmembrane segment and a cytoplasmic domain and 
IL-lR-AcP is in close proximity. IL-1 initially binds with 
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low affinity and IL-lR-AcP combines with and stabilizes the 
complex, which creates a high binding affinity and 
stimulates a strong signal transduction. IL-lRl is 
essential for all IL-1 induced biological actions [52]. The 
cell bound IL-1R2 does not transduce a signal; it appears 
to act as a "sink" for IL-1~ to restrain the effects of IL-
1~. As with the TNF receptors, the extracellular domains of 
the type I and type II receptors are cleaved and found as 
soluble molecules that also compete for binding to IL-la, 
IL-1~ and IL-lRa [29, 58]. 
IL-1 Signal Transduction 
The effect of IL-1 signal transduction is eventually the 
activation and suppression of transcription factors that 
regulate genes responsible for cellular activities. Upon 
binding and forming a stable receptor ligand complex, 
myeloid differentiation factor 88 (MyD88) links to the 
cytoplasmic TIR portion of the receptor and functions as an 
adapter molecule to link the receptor to downstream 
signaling molecules. The death domain (DD) portions of the 
My088 then combine with IL-1 receptor-associated kinase-2 
(IRAK-2), which is quickly phosphorylated. The 
phosphorylated form then combines with TNF receptor-
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associated factor 6 (TRAF-6), which is then acted on by 
kinases. The kinase activity then begins a cascade of 
protein interactions and phosphorylations, which modify the 
ability of transcription factors to turn on specific genes 
[ 5 9 J • 
Experimental Models for TNF and IL-1 
To determine the effects of TNF and IL-1, several methods 
have been used: human subjects, monoclonal antibodies [2], 
soluble receptors and transgenic mice; mice that have been 
genetically altered so as to be deficient of a receptor 
[52] or a specific cytokine. The monoclonal antibody method 
has been used on TNF receptors in vitro [34] to assess the 
cytokine's effect on human endothelial cell function [39]. 
Experiments have used soluble receptors to assess bone loss 
in periodontitis in simians[60] and inhibit ocular 
inflammation in humans[61]. Combinations of soluble 
receptors and transgenic mice have been used to study 
neural growth after inflammation [62], promote corneal 
graft survival [63], treat autosomal arthritic 
diseases[64], and inhibit cutaneous inflammation[65]. 
Most studies have indicated that, in the presence of 
sepsis, TNF and IL-1 inhibit the healing process. In a 
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study by Maish [4], the effects of TNF on incisional wound 
healing in the presence of induced, chronic abdominal 
abscesses were measured. The breaking strength of 
incisional wounds was decreased by 40 percent in septic 
rats, while rats that were administered TNFbp, a specific 
TNF antagonist, significantly improved incisional wound 
healing strength, but not to control levels. 
Another Study by Maish determined that IL-lRa mediated the 
effects of TNF on healing under infection [5). The strength 
of abdominal incisions in rats was compared among three 
groups of rats: a control group; a TNF injected group, and 
a TNF/IL-lRa injected group. The TNF group had shown a 
decrease in the breaking strength of incisional wounds to 
40 percent of control levels, whereas the TNF/ IL- lRa 
group had restored the breaking strength of incisions from 
TNF-infused animals to 80 percent of control levels. 
Furthermore, in a study by Rapala [17], it was determined 
that application of TNF inhibited wound repair and 
accumulation of collagen. 
In a murine calvarial experiment by Childs et al, the 
effect of sTNFR inhibitors on debris induced osteolysis in 
the presence of titanium particles imbedded into athymic, 
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transgenic mice calvaria was measured. The results 
indicated that sTNFR: Fe gene therapy reduced bone 
resorption [7]. 
Because IL-1 is the most potent inflammatory cytokine and 
most tissue damage results from the inflammatory response, 
experiments have been conducted to determine how the lack 
of IL-1 in an area of injury affects wound healing. 
Experimental results from Yamada [63] on C57BL/6 mice 
suggested that application of IL-lRa to corneal 
transplants increased the average healing time by one 
month through suppression of the inflammatory response. 
Inflammation 
Inflammation is a protective response that rids the body of 
organisms and substances that cause cellular injury. The 
inflammatory process removes necrotic tissue and invading 
microorganisms resulting from the injury. Inflammation has 
two phases: acute and chronic. The key characteristics of 
acute inflammation are the exudation of fluid and plasma 
proteins, and emigration of leukocytes, particularly 
neutrophils. Chronic inflammation is longer in duration 
and is associated with infiltration of T-lymphocytes and 
macrophages and the proliferation of blood vessels and 
26 
connective tissue. Vascular and cellular responses in 
inflammation are mediated by factors derived from plasma 
cells and triggered by inflammatory stimuli. First, 
vasodilation occurs, followed by a slowing of the 
circulation resulting from the increased permeability 
brought on by histamine, serotonin, and bradykinin. These 
mediators act as chemical mediators, which cause 
endothelial cells to contract, producing intercellular gaps 
through which substances can pass. Leukocytic margination, 
rolling, and adhesion then take place. As the first 
adhesive event, these cells begin to roll over endothelial 
cells. This rolling is mediated by selectins and occurs 
within minutes of cell injury. The selectin family of 
adhesion molecules mediates the initial attachment of 
leukocytes to endothelial cells before their firm adhesion 
to sites of tissue injury and inflammation. Selectins are 
expressed on three cell types: endothelial cells, 
platelets, and leukocytes. Leukocytes then move to the 
periphery of the vessel and come in contact with the vessel 
wall. After the process of margination, these cells at 
their final stage begin to attach to the endothelium of the 
vessel. This attaching process is called adhesion. 
Inflammatory mediators such as TNF and IL-1 can stimulate 
synthesis of these adhesion molecules on endothelial cells 
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(ELAM-1, ICAM-1) and leukocytes (LFA-1, MO-1, p-150, CD-11, 
CD-18 on neutrophils). Subsequent to adhesion and 
stimulation by the adhesive interaction, leukocytes insert 
their pseudopods into the junction between the endothelial 
cells, press through interendothelial junctions, and move 
into the space between endothelial cells and basement 
membrane. At this point they navigate the basement 
membrane and migrate into the extravascular space. 
Thereafter, leukocytes migrate toward chemotactic stimuli 
and the site of the injury where phagocytosis and 
intracellular degradation could occur. On the other hand, 
chronic inflammation involves a proliferative response 
relating to fibroblasts and vascular endothelium. It is 
characterized by infiltration and influx of mononuclear 
cells such as plasma cells, lymphocytes, and macrophages 
causing fibrosis and destruction of the tissue. 
IL-1 and TNF in Wound Healing 
Soft Tissue 
Cutaneous wound healing occurs in three primary stages: 
inflammation, tissue formation, and tissue remodeling. 
Each stage involves a wide range of cellular, molecular, 
and biochemical processes. 
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The inflammatory stage is an acute reaction that seeks to 
limit tissue disturbances and spread of infection caused by 
a wound. After the formation of the fibrin/ fibronectin 
clot and subsequent attachment of platelets, growth factors 
are released that stimulate macrophages and fibroblasts, as 
well as other cells, to produce TNF and IL-1. This begins 
a cascade effect to stimulate mitogenesis in lymphocytes, 
and chemotaxis for inflammatory cells by both TNF and IL-1. 
IL-1 also initiates the upregulation of cellular adhesion 
molecules in endothelial cells to aid in diapedesis [66]. 
Furthermore, TNF plays a role in angiogenesis as a growth 
factor [67, 68] during the tissue formation stage. As the 
cellular debris is cleared away, macrophages as well as 
fibroblasts continue to produce cytokines and growth 
factors. TNF and the growth factors stimulate the 
endothelial cells to produce enzymes that facilitate the 
breakdown of the surrounding matrix allowing the 
endothelial cells to migrate in a bud-like fashion toward 
the attractants [68]. 
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Osseous Wound Healing 
In order for an osseous wound to heal, it must first 
undergo preparation of the wound site by osteoclasts. To 
begin the process, osteoclasts must differentiate, migrate, 
and attach to the bone surface. Regulation of these 
processes is mediated by cytokines and growth factors, 
which may be released by the bone matrix due to injury 
[69]. TNF, a product of activated macrophages, is among 
the most potent of osteoclastogenic cytokines [70]. 
Interleukin-1 is also a very potent stimulator of both 
mature osteoclasts and the proliferation of osteoclast 
precursors. It acts synergistically with other mediators 
such as PTH, TNF and TGF to stimulate osteoclast formation 
and subsequent resorption[71]. Stimulated osteoclasts then 
attach to the bone matrix proteins osteocalcin and 
osteopontin via integrin binding[72] and begin the 
resorptive process at their ruffled borders. 
Newly developing information indicates that the osteoblast 
may be the central cell through which bone resorption as 
well as bone formation is mediated[73]. It is thought that 
osteoblasts produce monocyte chemoattractant protein-1 
(MCP-1) due to stimulation by inflammatory mediators such 
as IL-1 and TNF. MCP-1 recruitment of monocytes into the 
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area of injury has been associated with increased numbers 
of osteoblasts [74, 75]. Osteoblasts then release factors, 
which enhances the activation of osteoclasts. Zaidi [76] 
demonstrated that the osteoclast activity is reversed by 
high calcium levels and calmodulin. Osteoblasts are then 
activated by growth factors that were released from the 
bone matrix during the resorptive stage and the bone 
formation stage begins. 
Materials and Methods 
For all data points in these experiments, two sections 
(microscopic slides) were examined per animal and the mean 
of the two sections was recorded as the value for a given 
specimen. 
Experimental Animals 
Soft Tissue 
A total of 81 experimental animals were used in the soft 
tissue portion of the project. Twenty-seven ·c57BL/6 x 129 
Fl normal hybrid mice between the ages of 8-14 weeks were 
used as controls, while twenty-seven mice with targeted 
deletions of the TNF type I and type II receptors (TNFRp55 -
I- - p75 -/-) and twenty-seven mice with targeted deletions 
of the IL-1 receptor (IL-1R_ 1_) were used as the 
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experimental groups. Deletions of the targeted genes were 
verified by polymerase chain reaction (PCR) that could 
distinguish between homozygous or heterozygous mice with 
targeted deletions and wild-type mice. All mice were 
obtained from Jackson Laboratories (Bar Harbor, ME). 
Hard Tissue 
In the hard tissue experiment, sixty experimental animals 
were examined. There were six groups of ten mice; each 
group contained four wild-type, three IL-Rl -I-, and three 
TNFR -!-_ As with the soft tissue experiment, mice with 
targeted deletions of the TNF type I and type II receptors 
(TNFRp55 -/- - p75 -/-) and mice with targeted deletions of 
the IL-1 receptor (IL-1R_ 1_) were used as the experimental 
groups and C57BL/6 x 129 F2 normal hybrid mice were used as 
the control groups. All mice were between the ages of 8-14 
weeks and were obtained from Jackson Laboratories (Bar 
Harbor, ME) . 
Creation of Soft Tissue Lesion 
Mice were anesthetized by a 0 .15 ml / (150ul) subcutaneous 
injection of a solution containing 1.0 ml Ketamine HCl 
(l00mg/ml) [Ketaset, Fort Dodge, IA] + 1. 0 ml Xylazine 
inj. (20mg/ml) [Rompum, Columbus, OH] + 6. 0 ml of sterile 
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phosphate-buffered saline (PBS) solution. First the area 
of the lesion was shaved and rinsed with sterile saline. 
Then a full thickness 1.5ml diameter punch biopsy was taken 
on the left side of the scalp at the mid-point between the 
sagittal suture, the ear and the eye. The mice were kept 
in a controlled environment and fed a standardized diet 
until they were sacrificed at the time points 0, 2, 4, 7, 
and 14 days. At the Day 0 time point, three wild-type, 
TNF, and IL-1 mice were sacrificed to establish a base line 
wound size; at all other time points, six mice of each 
group were sacrificed. 
Creation of Hard Tissue Lesion 
Each mouse was injected with approximately 0.05ml (50ul) of 
100,000 IU/Kg Pen G potassium (Ambi-pen, Schein Inc) one 
day prior to surgery and one day post surgery. A 
subcutaneous injection of 0.15 ml (150ul) of anesthesia 
solution (1.0 ml Ketamine HCl (l00mg/ml) [Ketaset, Fort 
Dodge, IA] + 1. 0 ml Xylazine inj. (20mg/;ml) [Rompum, 
Columbus, OH] + 6.0 ml of sterile phosphate-buffered 
saline) was given to each mouse. The area to be incised 
was washed with Betadine, shaved with a BIC™ razor, rinsed 
with sterile water, and scrubbed again with Betadine. A 
full thickness incision, beginning from the posterior 
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midline of the skull extending anterior to approximately 
2mm from ocular midpoint, was made and the tissue 
retracted. At a point approximately 2mm from the sagittal 
suture and 3mm anterior to the occipital suture, a 1.0mm 
diameter osteoectomy was made using a surgical #35 carbide 
bur (SS White Co.) in a Dremmel electric motor (The Dremmel 
Co.) at approximately 45,000 rpm to a point where the bur 
penetrated to the endosteum. Complete penetration of the 
calvaria was verified using a 016 endodontic explorer (Hu-
Friedy). The flap was then closed with 5-0 silk suture 
(Davis & Geck) using one mattress suture centrally located 
and two interrupted sutures each approximately 2mm from the 
anterior and posterior portion of the wound. Each mouse 
was given 0.05ml of Buprenex (analgesic)immediately, then 
12 and 24 hours post-surgery. The mice were kept in a 
controlled environment and fed a standardized diet until 
the wild-type mice were sacrificed at the time points of 0, 
3, 7, and 14 days and the IL-Rl - / - and TNF -/- mice were 
sacrificed at the time points of 3, 7, and 14 days. 
Preparation of Specimens 
The mice were sacrificed by a 1.0ml subcutaneous injection 
of anesthetic solution followed by CO2 overdose. 
dissection, each animal was cervically dislocated. 
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Before 
After 
the mice were sacrificed, the head of each animal was 
dissected free and then placed in 4 percent paraformaldhyde 
solution for 72 hours; the solution was changed at 
approximately 12-hour intervals. After fixation, a tissue 
specimen of approximately 10mm X 6mm containing the 
calvaria and soft tissue portion of the lesion were 
dissected intact. The specimens were then washed with 
solutions of lx PBS with 5~ 0 ' 10 %, and 15 % glycerin (pH of 
7. 2) for 15 min at 4°C for each solution concentration. 
Each specimen was then decalcified by placement in a Histo-
tissue capsule and immersed in Immunocal for 72 hours at 4°C 
and agitated at slow speed. Placing the specimens in Cal-
arrest for two 20-minute periods at 4°C neutralized the 
decalcification process. All specimens were then immersed 
in 30 percent sucrose solution for 24 hours at 10°C. In 
preparation for sectioning, the specimens were ' embedded in 
Histo Prep mounting media (Fisher) using dry ice to 
solidify the specimen and media and then in a 15 ml 
container of 2 methyl-butane solution at -80°C. 
Soft Tissue Sectioning 
The specimens were sectioned using a cryostat microtome 
(Leica, NY) until the margin of the soft tissue lesion was 
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verified under a light microscope and then contiguous 
transverse plane sections of 5-6 micrometer thickness were 
collected. The entire lesion was sectioned. 
Hard Tissue Sectioning 
As with the soft tissue sectioning, the onset of the bony 
lesion was verified under a light microscope and the entire 
lesion was sectioned. However, the sections were cut in a 
sagittal plane. 
Hematoxylin and Eosin Staining 
Every third section of the soft and hard tissue specimens 
was stained with hematoxylin and eosin. Slides were placed 
into a holder and immersed in hematoxylin for six minutes, 
after which they were dipped in four separate containers of 
distilled water. Slides were then immersed sequentially in 
containers of acid EtOH, distilled water, ammonium 
hydroxide, and distilled water for 30 seconds ea~h. The 
slides were then placed into eosin for one minute. 
Containers of EtOH at 85, 95, and 100 percent, 
respectively, were then used to immerse the slides for 
three minutes each. The slides were then brought to a fume 
hood where they were placed in two separate containers of 
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xylene for three minutes each. Finally, the slides were 
dried and cover-slipped with Permount. 
Assessment of Soft Tissue Healing 
The healing parameters of the epithelial gap, connective 
tissue gap, area of healing and number of PMNs (as a 
measure of inflammation) was assessed by histomorphological 
analysis of day 0, 2, 4, 7, and 14. The widest portion of 
the wound was used as the baseline healing parameter so as 
not to skew the results to a more rapid healing assessment. 
A microscopic image of the wound was measured by use of an 
image-processing system, which included the following 
equipment: a light microscope at 20X magnification, color 
camera (Sony high definition RGB), color image processor 
(Image-Pro Plus software), and personal computer (IBM 
compatible computer system). Each slide was examined to 
determine the widest section of the lesion. The distance 
between the leading edges of the epithelium and connective 
tissue were measured to determine the epithelial and 
connective tissue gaps, respectively. 
The area of healing was determined by Image-Pro Plus 
software calculations using a template, which was designed 
to measure the average area of the biopsy at the Day O time 
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point. The template measurements consisted of the height 
of the tissue at the margins of the lesion from the bony 
floor to the epithelium and the distance between the edges 
of the lesion. The area inside the rhomboid was then 
determined to be equivalent to the tissue removed by the 
biopsy or complete healing. 
PMNs were assessed with a light microscope under oil 
immersion at lOOOX magnification by counting the number of 
eosinophils and polymorphonuclear cells in ten fields at 
each edge of the lesion for a total of 20 fields per 
section. The fields of study contained the connective 
tissue extending from the superior border of the periosteum 
up to the inferior border of the epithelium height and as 
many fields in width to bring the total area examined up to 
10 per side for each section. At low magnification (lOx) 
these fields contained the most active area of 
inflammation. PMNs were accepted according to the darkly 
stained, multilobular "u" shaped nuclear characteristics. 
Eosinophils were accepted according to their brightly 
stained red granules. 
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Assessment of Hard Tissue Healing 
The widest portion of the osseous gap and length of new 
bone formation were the parameters used to measure osseous 
h€aling. Each slide was examined with light microscope and 
Image-Pro Plus software. As with the soft tissue aspect of 
the experiment, the widest portion of the wound was used as 
the baseline-healing factor so as not to skew the results 
to a more rapid healing assessment. The length of new bone 
formation was evident microscopically by the pattern of 
bone deposition and the difference in staining. Using the 
Image-Pro Plus system, the length of new bone from each 
side of the lesion was measured, added, and the mean 
derived. 
Statistical Analysis 
Using the method described above to determine the widest 
portion of the lesion, the widest two slides/specimen were 
used to analyze the healing process. The numerical values 
assigned to that animal were entered on a Microsoft® Excel 
spreadsheet. Then the mean, the standard deviation and the 
standard error were calculated on each respective 
experimental group at the time points of 0, 2, 4, 7, and 14 
days for the soft tissue study and 0, 3, 7, and 14 days for 
the hard tissue study. Afterwards, each slide's identity 
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was covered with masking tape and randomly assigned a new 
coded identity. All slides were analyzed in a double-blind 
fashion. Furthermore, a 33 percent inter-examiner and a 10 
percent intra-examiner assessment were performed randomly 
to verify accuracy. All measurements were recorded 
manually and electronically. An F-test (p<0.05) was 
performed to determine significant differences, if any, 
between the experimental and control groups. 
Results 
Previous experiments studied the effects of the cytokines 
IL-1 and TNF on the healing process under conditions of 
sepsis [ 4, 5, 1 7] . In our experiments we tested the 
hypothesis that the cytokines IL-1 and TNF, in the absence 
of sepsis, are necessary for the healing process in both 
osseous and soft tissues. This in-vivo study used 
calvarial and scalp models of mice with targeted deletions 
of the IL-1 type I receptor (IL-lR1- 1-), the TNF receptors 
p55-/- and p7 5 -/-, and the matching wild-type group 
(C57BL/6xl29 Fl hybrids) as controls. Lesions were created 
in these mice and healing was assessed as previously 
described. Histological slides were evaluated under light 
microscopy for the interepithelial distance, 
interconnective tissue distance, area of healing, and the 
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presence of PMNs (as a measure of inflammation) for the 
soft tissue experiment The length of new bone formation and 
the osseous gap were measured to assess healing for the 
osseous experiment. An F-test was used to determine 
statistical significance. 
Soft Tissue Results 
Figure 1 shows the number of PMNs per field present over 
the 14-day trial for all groups. As expected, the number 
of inflammatory cells increased for the first two days 
post-biopsy, indicating mild inflammation. As healing 
progressed, the PMN count of wild type and IL-lR- /- peaked 
from Day 2 to Day 4, then dropped to approximately pre-
biopsy levels by Day 7. The TNFR-/- group decreased earlier, 
on day 4. There were no clinical signs of infection or 
histological evidence of significant inflammation in any of 
the groups. 
Figures 2 and 3 represent the progression of healing for 
the epithelium and connective tissue, respectively. 
Healing in the TNF and IL-1 receptor deficient and control 
mice was similar at two and four days after wounding. 
However, at the Day 7 time point, there was complete 
healing for the wild-type mice and significantly less 
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connective tissue and epithelial healing for animals 
lacking TNF and IL-1 receptors (Figure 2, 3, 4), as 
determined by an F-test (p<0.05). We observed that healing 
in the experimental groups slowed between day 2 and 7 and 
was completely healed by day 14 with no significant 
difference when compared to the control group at that time 
point (Figure 4). 
The results of the soft tissue experiment are as follows: 
► Inflammation was minimal throughout the study. 
► The IL-lR -/- and the TNFR-/- groups demonstrated 
delayed healing from day 2 to day 7 and complete 
healing by day 14. 
► The control group demonstrated complete healing by day 
7 . 
Hard Tissue Results 
Preliminary experiments on wild-type mice indicated a 1.0mm 
osteotomy would completely heal by Day 14. Based on that 
information, 1.0mm diameter lesions were created in the 
control and experimental groups and healing was assessed at 
Day 3, 7, and 14. However, complete healing was not 
observed in any of the groups. In retrospect, Day 14 
should have been the first time point and a Day 28 should 
have been the final time point to best assess the osseous 
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healing rates. Day 14 of the hard tissue experiment was 
the only time point from which any pertinent data could be 
utilized. Figure 5 compares the size of the original gap 
between the experimental and control groups. The original 
gap created by the lesion was discerned using a light 
microscope and measured using Image-Pro Plus software under 
X40 magnification. The older bone is differentiated from 
the new bone growth by its uniform structural appearance, 
the presence of osteocytes, and darker red staining. The 
newly formed bone was irregular in structure and usually 
stained lighter than the mature bone (Figures 6 and 6A). 
The graph in Figure SA indicates the progression of new 
bone growth into the osteotomy. As with the soft tissue 
experiment, the mice lacking the receptors for IL-1 and TNF 
exhibited a delay in healing. The statistical significance 
of these results could not be determined due to the death 
of one control and one IL-lR - /- mouse and the unreadable 
nature of cryostat sections from one control and one TNF 
receptor deficient mouse. The remaining number of mice in 
each group was not large enough to be statistically viable. 
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Fig. 1. Comparison of PMN Levels 
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Recruitment of PMNs is similar in TNFR pss -1-p75 -/- , IL-lR- / - and wild-type 
mice in excisional wounds of the scalp at Day 2 and 7. There was a 
significant difference (p <0.05) between IL-1 and the wild-type at Day 
4. A 1.5mm biopsy was placed in the scalp as previously described. 
PMNs were counted in H&E stained sections at lOOOx magnification in the 
healing connective tissue. There were no significant differences 
(p>0.05) between all groups at Day 2 and 7. 
Mean (Std Error) Wild Type IL-lR-/- TNF p55-/p75-
Day 0 0.406(+/-0.126) 0.097(+/-0.1) 0.193(+/-0.219) 
Day 2 1. 785 (+/-0. 675) 1.312(+/-0.499) 1.068 (+/-0.475) 
Day 4 1.901(+/-0.573) 0.525(+/-0.385) 1.286(+/-0.788) 
Day 7 0.457(+/-0.373) 0.54(+/-0.372) 0.614(+/-0.266) 
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Fig. 2. Interepithelial Gap/Progression of Healing 
Epithelial healing of excisional wounds in the scalp is similar between 
the experimental and control groups. A 1.5mm diameter excisional scalp 
wound was created at a midpoint between the ears. The animals were 
sacrificed at Day 0, 2, 4, 7, and 14. Histological measurements of the 
epithelial gap were made from H&E stained sections at the widest point 
of the lesion. There was a significant difference between the 
experimental and control groups only on Day 7 (p<0.05). Original 
magnification X40. 
Mean(Std Error) Wild Type IL-lR-/- TNFR p55-/p75-
Day 0 1.86(+/-0.216) 1. 32 (+/-0. 313) 1.51(+/-0.298) 
Day 2 1.201(+/-0.654) 0.73(+/-0.368) 1.32 (+/-0.368) 
Day 4 0.83(+/-0.656) 0.75(+/-0.373) 1. 04 (+/-0. 671) 
Day 7 0.12(+/-0.261) 0.64(+/-0.281) 0.86(+/-0. 722) 
Day 14 0.12(+/-0.269) 0 .11 (+/-0. 243) 0.27(+/-0.616) 
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Fig. 3. Interconnective Tissue Gap/Progression of Healing 
Connective tissue healing of excisional wounds in the scalp is similar 
between the experimental and control groups. A 1.5mm diameter 
excisional scalp wound was created at a midpoint between the ears. The 
animals were sacrificed at Day 0, 2, 4, 7, and 14. Histological 
measurements of the connective tissue gap were made from H&E stained 
sections at the widest point of the lesion. There was a significant 
difference between the experimental and control groups only on Day 7 
(p<0.05). Original magnification X40. 
Mean (Std Error) Wild Type IL-lR-/- TNFR p55-/p75-
Day 0 1.89(+/-0.24) 1.35(+/-0.322) 1.58{+/-0.305) 
Day 2 1.26(+/-0.674) 1.16 (+/-0. 928) 1.37 (+/-0.347) 
Day 4 0.927 (+/-0. 715) 0.823(+/-0.407) 1.09(+/-0.689) 
Day 7 0.13(+/-0.291) 0.675(+/-0.29) 1.22 (+/-0. 71) 
Day 14 0.14(+/-0.313) 0 .115 (+/-0. 257) 0.286(+/-0.642) 
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Area of healing of excisional wounds in the scalp is similar between 
the experimental and control groups. A 1.5mm diameter excisional scalp 
wound was created at a midpoint between the ears. The animals were 
sacrificed at Day 0, 2, 4, 7, and 14. Histological measurements of the 
area (square millimeters) of healing were made from H&E stained 
sections using a template. There was a significant difference between 
the experimental and control groups only on Day 7 (p<0.05). Original 
magnification X40. · 
Mean 
(Std Error) Wild type IL-lR-/- TNFR P55-/P75-
0.019(+/-
Day 0 0(+/- 0) 0.52(+/- 0.047) 0.015) 
0.071(+/-
Day 2 0.095(+/- 0.095) 0.11(+/- 0.119) 0.048) 
0.144(+/-
Day 4 0.187(+/-0.0390) 0.196 (+/- 0.097) 0.108) 
0.11(+/-
Day 7 0.368(+/- 0. 059) 0.329(+/- 0.1490) 0.143) 
0.309(+/-
Day 14 0.361(+/- 0.074) 0.331(+/- 0.143) 0.107) 
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Fig. 4A. Photomicrograph Wild-Type Soft Tissue Healing at Day 14 
Area of healing of an excisional scalp wound is complete by Day 7 in a 
wild - type animal . A 1 . 5mm diameter wound was placed midpoint between 
the ears . Specimens were prepared for cryostat sectioning and stained 
with H&E. The area of healing is indicated by the absence of hair 
follicles . Original magnification X40 
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Fig. 5. Original Osseous Gap 
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The original osseous gap is similar for the TNF p55-/p75-, IL-lR- / - and 
wild-type mice. The 1.0mm osteotomy was created at the midpoint 
between the junction of the sagittal and occipital sutures, and the 
orbit. The animals were sacrificed 14 days later. Specimens were 
prepared for cryostat sectioning and stained with H&E. Measurements 
were calculated using Image-Pro Plus software under X40 magnification. 
The darker staining bone and the presence of osteocytes differentiate 
the mature from the new bone (Figures 6 and 6A). Statistical data is 
not viable due to the expiration of two wild-type mice and the unusable 
nature of a cryostat specimen from each experimental group. Original 
magnification X40 . 
Day 14 Wild Type IL-lR-/- TNFR P55-/P75-
Mean (Std Error ) 1.21 (+/-0.0518) 1.07(+/-0.0425 ) 1.078(+/-0.0358 ) 
49 
Length of New Bone Day 14 
0.9 
0.8 
0.7 
0.6 
E 0.5 
E 0.4 
0. 3 --+-----
0 .2 
0.1 
0 -----
Fig. SA. Length of New Bone Growth Day 14 
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New bone growth into osseous gap at Day 14 is delayed in TNF p55-/p75-
and IL-lR- / - mice compared to wild-type mice. The lesion was created and 
the specimens were prepared and measured as described in Figure 5. 
Statistical data is not viable due to the expiration of a wild-type 
mouse and the unusable nature of a cryostat specimen from each 
experimental group. Original magnification X40. 
Day 14 Wild Type IL-lR-/- TNFR p55-/p75-
~ean(+/-) 0.61(+/-0.203) 0.368(+/-0.174) 0.2595(+/-0.153) 
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TNF p55-/p75-Osseous Healing 
at 
Day 14 
Fig. 6. Photomicrograph TNF p55-/p75- Osseous Healing at Day 14 
Incomplete healing of osteotomy in TNF p55 - /p75 - animal at Day 14 . The 
lesion was created and the specimens were prepared and measured as 
described in Figure 5 . The darker staining bone and the presence of 
osteocytes differentiate the mature from the new bone . Original 
magnification X40 
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Fig. 6A. Photomicrograph of Wild-Type Osseous Healing at Day 14 
Partial healing of osteotomy in a wild-type mouse at Day 14. The 
lesion was created and the specimens were prepared and measured as 
described in Figure 5. The darker staining bone and the presence of 
osteocytes differentiate the mature from the new bone. Original 
magnification X40 
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Discussion 
The role of IL-1 and TNF during the early inflammatory 
phase of wound healing has been well established [29, 49, 
66, 77, 78]. However, little research has been conducted 
on the activity of IL-1 and TNF in the tissue formation 
stage of wound healing. These experiments demonstrate that 
IL-1 and TNF activity is necessary for initial tissue 
formation in wound repair. 
In the soft tissue experiment, the scalp biopsy created 
trauma and initiated the early inflammatory response by 
producing an increase in the number of PMNs (Figure 1), a 
marker of inflammation. Due to the low bacterial load of 
the scalp, this inflammatory response was not likely caused 
by sepsis [79]. These soft tissue inflammatory events do 
not seem to be affected by the absence of TNF and IL-1 
activity as indicated by Figure 1. For all groups there was 
a significant increase in the number of PMNs by Day 2. The 
size of the inflammatory infiltrate decreased considerably 
in all groups by Day 7, although they were still above 
baseline levels. This evidence suggests the effect of other 
up regulators of the inflammatory response different from 
TNF and IL-1. 
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The physical trauma from the excisional scalp biopsy caused 
blood vessel disruption and hence platelet aggregation and 
blood clot formation. These coagulation events initiated 
non-cytokine proinflammatory mediators, such as PGE2, 
bradykinin, and the complement cascade. In turn, numerous 
chemotactic factors that recruit leukocytes to the injured 
site were produced [66, 80], which account for the increase 
in PMN infiltration to the trauma site in the absence of 
IL-1 and TNF activity. 
We observed a consistent, reproducible lag at a later time 
point that is subtle. A comparison of the experimental and 
control groups indicated that both the epithelial and 
connective tissue rates of healing were not significantly 
different at day 2, 4, and 14 (Figures 2 and 3). Day 7 
produced significant differences (p<0.05) in epithelial and 
connective tissue repair. Subsequently, all groups 
demonstrated complete healing at day 14. Another 
measurement of the healing progression, the area of healing 
(Figure 4), revealed the same subtle lag in repair at day 
7. As with the epithelial and connective measurements, the 
rate of healing was not significantly different on day 2, 
4, and 14. The area of healing is important because it 
demonstrates the completeness of wound repair ( Figure 4A). 
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The volume of connective tissue regenerated in the wound, 
as well as its epithelial covering, demonstrated that the 
wound did not simply re-epithelialize. 
The evidence indicates that IL-1 and TNF may support the 
formation of later stage granulation tissue development. 
This may be accomplished by any combination of three means: 
TNF and IL-1 activity may be responsible, in part, for the 
proliferation of fibroblasts and their subsequent effects 
on granulation tissue formation; the cytokines may affect 
apoptosis in the area of trauma; and, IL-1 and TNF activity 
may have a differentiated function in the production of 
matrix proteins. 
Fibroblasts undergo a series of morphogenetic changes 
during granulation tissue formation. Initially, they 
migrate to the wound space and produce collagen. 
Stimulated by factors not yet determined, fibroblasts then 
decrease collagen production and are upregulated to produce 
non-muscle actin filaments, which compact the connective 
tissue and contract the wound [66, 81]. The lag in healing 
demonstrated at the Day 7 time point by the experimental 
groups (Figures 2, 3, 4, and 4A), may represent the subtle 
influences the lack of TNF and IL-1 activity may have on 
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fibroblast proliferation. The concurrent equilization of 
the healing rate is possibly due to the redundant effects 
of other mediators of wound healing. 
Furthermore, TNF and the commensurate level of IL-1 have 
been demonstrated to stimulate collagenase production in 
fibroblasts suggesting they may play a role in tissue 
destruction and remodeling [82]. Short-term collagenase 
production is beneficial in that it degrades damaged 
collagen fibers and allows for the production of reparative 
tissue. Chronic collagenase production is injurious as it 
continues the destruction of collagen fibers resulting in a 
non-healing wound. Without the upregulation by TNF and IL-
1, fibroblasts may not produce the enzymes and collagen 
fibers necessary for healing progression. 
The roles of IL-1 and TNF in apoptosis are not clear and 
many mechanisms have been proposed [83]. TNF activity has 
been associated with apoptosis in endothelial cells [84], 
and in T-lymphocytes in conjunction with IL-1 [45]. TNF has 
been suspected to mediate the effects of other inducers of 
apoptosis as well [47]. In the absence of IL-1 and TNF 
induced apoptosis in inflammatory cells, their prolonged 
activity would create a delay in healing until other 
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mediators of apoptosis could affect the immune cells. The 
delay observed in the soft tissue healing could be caused 
by a persistent PMN infiltrate [79] and the subsequent 
inhibition of fibroblast proliferation. However, this is 
unlikely since persistent inflammation was not observed in 
the experimental groups. 
The inhibition of matrix protein production may also 
account for the pause in healing observed on Day 7 in the 
experimental groups. In an experiment conducted in our lab 
(unpublished data), blockage of TNF activity inhibited the 
production of procollagen I and III for up to 48 hours. 
That initial delay in those matrix proteins may account for 
the clinically observable lag in repair at Day 7. Similar 
data is not currently available for IL-1. 
In the hard tissue experiment, some pertinent information 
was obtained, although it could not be statistically proven 
due to the expiration of two mice and unreadable cryostat 
sections. 
• The experimental groups showed delayed healing 
compared to the wild type. 
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• All mice were treated with antibiotics, therefore the 
delay in healing was most likely due to the lack of 
TNF and IL-1 activity and not to sepsis [79]. 
• The length of new bone into the osseous wound was 
greater in the wild type when compared to TNF and IL-1 
receptor deficient mice. 
• A 1.0mm osteotomy appears to require more than 14 days 
to heal completely. 
Other models have used TNF and IL-1 receptor deficient mice 
to determine the cytokine roles in the healing process. 
These studies illustrated two important points: IL-1 and 
TNF possess a diversity of biological function and they are 
redundant in that they have overlapping effects with other 
cytokines. Their impact on the host incorporates responses 
to infectious disease, which may be beneficial if there is 
protection against infection, or deleterious if tissue 
injury and death occur. TNF illustrates this type of 
scenario: during local inflammation, low levels of TNF act 
to enhance immune responsiveness, stimulate blood-vessel 
growth, increase energy mobilization, induce the release of 
other cytokines, and promote wound-healing. If a persistent 
infection develops and TNF is chronically secreted, a 
failure to heal results [15]. 
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In a study on oral healing, 1.5mm punch biopsies were 
created on the palate in IL-lR-/- and wild-type mice. To 
reduce the effects of the oral flora, a regimen of 
antibiotics was used in two subgroups. The results from 
the antibiotic treated mice indicated that healing was 
impaired in the IL-lRl-/- mice when compared to the wild 
type. It would seem reasonable to extrapolate that the 
experimental group in the palatal excision study 
demonstrated delayed granulation tissue development as 
previously described. 
Another experiment studied the effects of excess IL-1 
activity on muscle protein synthesis [85]. In this study, 
various muscle groups were injected with IL-1. In both the 
slow-twitch and fast-twitch muscles, protein synthesis was 
significantly reduced. These findings support a regulatory 
role for IL-1 as a mediator of muscle protein synthesis, 
whereas overexpression will create a catabolic state. 
Other studies have also implicated the cytokines TNF and 
IL-1 as having beneficial effects such as myelo-
stimulation, as well as a role in the metabolic processes 
that provide substrates important in combating the results 
of injury [28]. The same study also found that exaggerated 
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or prolonged production of these proteins may produce 
detrimental effects that lead to a poor outcome. 
This mounting evidence suggests that IL-1 and TNF activity 
plays a balanced role in the stimulation of the substrates 
necessary for wound repair. The lack of IL-1 and TNF 
activity results in delayed healing, as demonstrated in our 
experiment, and overexpression inhibits the production of 
substrates and results in chronic lesions [28, 79]. 
Based on our findings in this experiment, it is meaningful 
to say that TNF and IL-1 activity is needed for normal 
progression of wound healing. However, in endodontics, the 
chronic periapical lesion or granuloma is marked by chronic 
apical inflammation. Bacteria and their metabolites from 
the canal create a long-term, low-grade response. The 
result is an inner layer of lymphocytes, macrophages, and 
plasma cells surrounded by a fibrous capsule of collagen, 
fibroblasts, and capillary buds. PMNs are also present 
suggesting a failure to resolve bacteria-induced 
inflammation[86]. In these lesions, the chronic presence of 
immune cells responsible for the production of IL-1 and TNF 
suggest the cytokines are consistently upregulated. As 
previous experiments have shown, overexpression of IL-1 and 
60 
TNF results in a prolonged inflammatory period and a poor 
healing result [ 2 8] . The placement of blockers into the 
lesion during endodontic therapy could aid in treatment of 
chronic periapical lesions by attenuating the inflammatory 
response that leads to prolonged healing. However, complete 
inhibition of IL-1 and TNF activity could pose problems in 
wound healing based upon delays in soft tissue and osseous 
tissue repair in mice lacking TNF activity. 
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